|
1
|
Zanders ED, Svensson F and Bailey DS:
Therapy for glioblastoma: Is it working? Drug Discov Today.
24:1193–1201. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stupp R, Taillibert S, Kanner A, Read W,
Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K,
et al: Effect of tumor-treating fields plus maintenance
temozolomide vs maintenance temozolomide alone on survival in
patients with glioblastoma: A randomized clinical trial. JAMA.
318:2306–2316. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ostrom QT, Gittleman H, Farah P, Ondracek
A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C and Barnholtz-Sloan JS:
CBTRUS statistical report: Primary brain and central nervous system
tumors diagnosed in the United States in 2006–2010. Neuro Oncol. 15
(Suppl 2):ii1–ii56. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ostrom QT, Gittleman H, Stetson L, Virk SM
and Barnholtz-Sloan JS: Epidemiology of gliomas. Cancer Treat Res.
163:1–14. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Santosh V, Sravya P, Gupta T, Muzumdar D,
Chacko G, Suri V, Epari S, Balasubramaniam A, Radotra BD,
Chatterjee S, et al: ISNO consensus guidelines for practical
adaptation of the WHO 2016 classification of adult diffuse gliomas.
Neurol India. 67:173–182. 2019.PubMed/NCBI
|
|
7
|
Molinaro AM, Taylor JW, Wiencke JK and
Wrensch MR: Genetic and molecular epidemiology of adult diffuse
glioma. Nat Rev Neurol. 15:405–417. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 world health organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Verdecchia A, De Angelis G and Capocaccia
R: Estimation and projections of cancer prevalence from cancer
registry data. Stat Med. 21:3511–3526. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lapointe S, Perry A and Butowski NA:
Primary brain tumours in adults. Lancet. 392:432–446. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Linz U: Commentary on effects of
radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised
phase III study: 5-year analysis of the EORTC-NCIC trial (Lancet
Oncol. 2009;10:459-466). Cancer. 116:1844–1846. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Anjum K, Shagufta BI, Abbas SQ, Patel S,
Khan I, Shah SAA, Akhter N and Hassan SSU: Current status and
future therapeutic perspectives of glioblastoma multiforme (GBM)
therapy: A review. Biomed Pharmacother. 92:681–689. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Aldape K, Zadeh G, Mansouri S,
Reifenberger G and von Deimling A: Glioblastoma: Pathology,
molecular mechanisms and markers. Acta Neuropathol. 129:829–848.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Park AK, Kim P, Ballester LY, Esquenazi Y
and Zhao Z: Subtype-specific signaling pathways and genomic
aberrations associated with prognosis of glioblastoma. Neuro Oncol.
21:59–70. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wojtas B, Gielniewski B, Wojnicki K,
Maleszewska M, Mondal SS, Nauman P, Grajkowska W, Glass R, Schüller
U, Herold-Mende C and Kaminska B: Gliosarcoma Is driven by
alterations in PI3K/AKT, RAS/MAPK pathways and characterized by
collagen gene expression signature. Cancers (Basel). 11(pii):
E2842019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang X, Yang JA, Liu BH, Liao JM, Yuan FE,
Tan YQ and Chen QX: TGX-221 inhibits proliferation and induces
apoptosis in human glioblastoma cells. Oncol Rep. 38:2836–2842.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu PF, Yang JA, Liu JH, Yang X, Liao JM,
Yuan FE, Liu BH and Chen QX: PI3Kβ inhibitor AZD6482 exerts
antiproliferative activity and induces apoptosis in human
glioblastoma cells. Oncol Rep. 41:125–132. 2019.PubMed/NCBI
|
|
19
|
Engelman JA: Targeting PI3K signalling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Noorolyai S, Shajari N, Baghbani E,
Sadreddini S and Baradaran B: The relation between PI3K/AKT
signalling pathway and cancer. Gene. 698:120–128. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Thorpe LM, Yuzugullu H and Zhao JJ: PI3K
in cancer: Divergent roles of isoforms, modes of activation and
therapeutic targeting. Nat Rev Cancer. 15:7–24. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wicki A, Brown N, Xyrafas A, Bize V, Hawle
H, Berardi S, Cmiljanović N, Cmiljanović V, Stumm M, Dimitrijević
S, et al: First-in human, phase 1, dose-escalation pharmacokinetic
and pharmacodynamic study of the oral dual PI3K and mTORC1/2
inhibitor PQR309 in patients with advanced solid tumors (SAKK
67/13). Eur J Cancer. 96:6–16. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Beaufils F, Cmiljanovic N, Cmiljanovic V,
Bohnacker T, Melone A, Marone R, Jackson E, Zhang X, Sele A,
Borsari C, et al:
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine
(PQR309), a potent, brain-penetrant, orally bioavailable, pan-class
I PI3K/mTOR inhibitor as clinical candidate in oncology. J Med
Chem. 60:7524–7538. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen H, Mei L, Zhou L, Shen X, Guo C,
Zheng Y, Zhu H, Zhu Y and Huang L: PTEN restoration and PIK3CB
knockdown synergistically suppress glioblastoma growth in vitro and
in xenografts. J Neurooncol. 104:155–167. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu P, Cheng H, Roberts TM and Zhao JJ:
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev
Drug Discov. 8:627–644. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tarantelli C, Gaudio E, Arribas AJ, Kwee
I, Hillmann P, Rinaldi A, Cascione L, Spriano F, Bernasconi E,
Guidetti F, et al: PQR309 is a novel dual PI3K/mTOR inhibitor with
preclinical antitumor activity in lymphomas as a single agent and
in combination therapy. Clin Cancer Res. 24:120–129. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang J, Li XM, Bai Z, Chi BX, Wei Y and
Chen X: Curcumol induces cell cycle arrest in colon cancer cells
via reactive oxygen species and Akt/ GSK3β/cyclin D1 pathway. J
Ethnopharmacol. 210:1–9. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Omuro A and DeAngelis LM: Glioblastoma and
other malignant gliomas: A clinical review. JAMA. 310:1842–1850.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Teodorczyk M and Martin-Villalba A:
Sensing invasion: Cell surface receptors driving spreading of
glioblastoma. J Cell Physiol. 222:1–10. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vastrad B, Vastrad C, Godavarthi A and
Chandrashekar R: Molecular mechanisms underlying gliomas and
glioblastoma pathogenesis revealed by bioinformatics analysis of
microarray data. Med Oncol. 34:1822017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sarbassov DD, Guertin DA, Ali SM and
Sabatini DM: Phosphorylation and regulation of AKT/PKB by the
rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang J and Manning BD: A complex
interplay between AKT, TSC2 and the two mTOR complexes. Biochem Soc
Trans. 37:217–222. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu X, Xu Y, Zhou Q, Chen M, Zhang Y,
Liang H, Zhao J, Zhong W and Wang M: PI3K in cancer: Its structure,
activation modes and role in shaping tumor microenvironment. Future
Oncol. 14:665–674. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hanker AB, Kaklamani V and Arteaga CL:
Challenges for the clinical development of PI3K inhibitors:
Strategies to improve their impact in solid tumors. Cancer Discov.
9:482–491. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yap TA, Bjerke L, Clarke PA and Workman P:
Drugging PI3K in cancer: Refining targets and therapeutic
strategies. Curr Opin Pharmacol. 23:98–107. 2015. View Article : Google Scholar : PubMed/NCBI
|
